Cargando…
Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. The persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1...
Autores principales: | Gui, Gege, Dillon, Laura W., Ravindra, Niveditha, Hegde, Pranay S., Andrew, Georgia, Mukherjee, Devdeep, Wong, Zoë, Auletta, Jeffery, El Chaer, Firas, Chen, Evan, Chen, Yi-Bin, Corner, Adam, Devine, Steven M., Iyer, Sunil, Jimenez Jimenez, Antonio Martin, De Lima, Marcos J.G., Litzow, Mark R., Kebriaei, Partow, Spellman, Stephen R, Zeger, Scott L., Page, Kristin M., Hourigan, Christopher S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418565/ https://www.ncbi.nlm.nih.gov/pubmed/37577695 http://dx.doi.org/10.1101/2023.07.28.23293166 |
Ejemplares similares
-
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
por: El Chaer, Firas, et al.
Publicado: (2022) -
How I treat AML incorporating the updated classifications and guidelines
por: El Chaer, Firas, et al.
Publicado: (2023) -
Mesenchymal Stem Cell Therapy in the Treatment of Acute and Chronic Graft Versus Host Disease
por: Kebriaei, Partow, et al.
Publicado: (2011) -
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
por: Versluis, Jurjen, et al.
Publicado: (2023) -
Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Impact Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic
por: Devine, Steven M., et al.
Publicado: (2022)